Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Xenetic Biosciences ( (XBIO) ) is now available.
On December 11, 2025, Xenetic Biosciences, Inc. announced that its 2025 Annual Meeting of Stockholders, originally scheduled for that day, was adjourned until January 8, 2026 to achieve a quorum and allow more time to solicit proxies on behalf of the board. When the meeting reconvened on January 8, 2026, it was again adjourned without any business conducted due to the continued lack of a requisite quorum, and the company now plans to reconvene the meeting at a future, yet-to-be-determined date, signaling ongoing stockholder engagement and governance challenges that could delay corporate decision-making.
The most recent analyst rating on (XBIO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Xenetic Biosciences stock, see the XBIO Stock Forecast page.
Spark’s Take on XBIO Stock
According to Spark, TipRanks’ AI Analyst, XBIO is a Neutral.
The score is held down primarily by persistent losses and negative free cash flow, despite some revenue improvement and a no-debt balance sheet. Technicals also weaken the outlook, with the stock trading below key moving averages and negative MACD. Valuation is difficult to justify with a negative P/E and no dividend data to offset risk.
To see Spark’s full report on XBIO stock, click here.
More about Xenetic Biosciences
Average Trading Volume: 81,741
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.97M
Learn more about XBIO stock on TipRanks’ Stock Analysis page.